19th Ave New York, NY 95822, USA

Team-Test

Mike Solomon, Ph.D.

John Reardon, Ph.D.

Buck Phillips

Katie Warner, Ph.D.

Kendra Hightower, Ph.D.

Don Hertzog, Ph.D.

Mike Solomon, Ph.D.

Mike has more than twenty years of experience in the biotechnology industry, with the last seventeen focused on creating and operating early stage therapeutic-focused companies.

Most recently, Mike was a Venture Partner at SV Health Investors which led the seed round for Ribometrix. Prior to that he was Chief Operating Officer at Decibel Therapeutics, a biotechnology company focused on broadly treating hearing disorders. Mike’s involvement at Decibel was part of his work as an Entrepreneur-in-Residence at Third Rock Ventures; he led a team that created Decibel’s business plan resulting in a $52 M Series A round.

Prior to Decibel, Mike was Chief Operating Officer at Ember Therapeutics, a Third Rock Ventures company focused on obesity and diabetes, and Chief Business Officer at Link Medicine, a neurodegeneration focused biotechnology company that was sold to Astra Zeneca. Mike was also a founder and VP of Discovery at Epizyme Therapeutics, a company focused on epigenetic modulators that is now a publicly traded company, and VP of Discovery at Hypnion, Inc a sleep disorder company that was sold to Lilly in 2007 for $325 million. Mike also spent two years as a biotechnology analyst at Bank of America Securities. He started his career at Millennium Pharmaceuticals, where he was project leader for multiple programs.

Mike received his BS in Chemistry from the University of Massachusetts at Amherst. He earned his Ph.D. in Organic Chemistry at the University of Wisconsin, and completed postdoctoral work in Synthetic Organic Chemistry at Scripps.

John Reardon, Ph.D.

John has more than thirty years of experience in the biopharmaceutical industry, with the last twelve spent in operational roles within small, virtual or partially virtual therapeutic-focused companies.

Most recently, John was Head of Research and Development at HemoShear Therapeutics and Chief Scientific Officer at Revivo Therapeutics; biotechnology companies focused on children’s rare diseases and neurodegeneration, respectively.

Prior to HemoShear and Revivo, John was Chief Scientific Officer at Cardioxyl Pharmaceuticals where he led the discovery and non-clinical development of two drugs for treatment of acute decompensated heart failure. Cardioxyl was sold to Bristol-Myers Squibb in 2015 for $2.2 billion. John was a founder and Executive Vice President of Research and Development at Integrated Oncology Solutions, a spin-out from Duke University prior to joining Cardioxyl.

Prior to John’s career in small biotech, he spent nineteen years with Burroughs Wellcome, Glaxo Wellcome and Glaxo Smith Kline, rising to the position of Senior Vice President of Discovery Research Biology where he oversaw all of the early lead discovery activities across all of the therapeutic areas at GSK.

John received his BS in Chemistry from Willamette University. He earned his Ph.D. in Chemistry at The Ohio State University and completed postdoctoral fellowship in Enzymology at Brandeis University.

Buck Phillips

Buck spent the last 30 years in the biotechnology industry, most recently as the managing member of Domantle Consulting LLC. From 2008 to May 2019, Buck served as the Chief Financial Officer for three separate NASDAQ listed, development stage biotechnology companies; G1 Therapeutics, Inc., GTHX, Novavax, NVAX, and Micromet, acquired by Amgen in 2012 for $1.2B. In addition to carrying the CFO role, he also held the title of SVP Corporate Development at G1 Therapeutics. During his tenure as CFO, Buck was responsible for all finance and accounting functions, financing strategy, successfully raising over $1.4B, Wall Street and investor relations, public relations and corporate strategy and corporate development.

Prior to his CFO experience, Buck had extensive experience in life science venture investing and public market investing, serving for 9 years as the Managing Director of Vector Fund Management, a late-stage life sciences venture capital fund with over $250 million in committed capital and approximately 30 venture investments in biotechnology, medical technology and healthcare services companies. In addition, he was Biotechnology Analyst and Director of Venture Investments for INVESCO Funds group, a no-load mutual fund family with a healthcare sector fund franchise totaling over $3.5 billion in assets under management.

He received a Bachelor of Arts degree in economics from the University of Colorado at Boulder.

Katie Warner, Ph.D.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Vivamus placerat bibendum felis vel efficitur. Phasellus eu imperdiet elit. Maecenas venenatis at odio eu viverra. Proin blandit justo mauris, et vehicula eros pulvinar ut. Curabitur faucibus tempor lectus, ac tincidunt lacus tempus commodo. Sed ut interdum lacus. Curabitur quam lectus, commodo eu venenatis non, iaculis sit amet metus. Nam nisl magna, euismod id mauris non, posuere vestibulum est. Quisque hendrerit arcu molestie neque convallis, eu lacinia mauris rutrum. Vestibulum quis turpis diam. Nam et felis id ipsum ultricies feugiat.

Kendra Hightower, Ph.D.

Kendra has over 25 years of experience in the chemical and biological sciences encompassing pharmaceutical, academic, and government R&D and pharmaceutical manufacturing. She spent 14 years at GlaxoSmithKline where she provided biochemical support and leadership for drug discovery programs across a wide range of drug targets and therapeutic areas including infectious diseases, oncology, and metabolic diseases. Ultimately, she co-led the Biological Sciences department at RTP which carried out reagent preparation, biochemical and cell-based assay development, compound screening, hit characterization, medicinal chemistry support, and mechanism of action studies for drug discovery and development programs. While at GlaxoSmithKline Kendra worked on two efforts that led to marketed drugs, the HIV integrase inhibitor Tivicay and the BRaf inhibitor Tafinlar. For Tivicay, biochemical studies conducted during the drug development process helped to differentiate the drug from competitor molecules and to better understand clinical response and integrase inhibitor resistance.

Outside of R&D, Kendra led a group which supported in-process bioassays, data analytics, compliance documentation, and process development for bulk live virus generation and vaccine fill/finish efforts at Merck Manufacturing Division. Prior to joining Ribometrix, Kendra was a Senior Study Director at Metabolon. In this role she was engaged in enabling and interpreting metabolomics studies to provide biological insights for projects across the pharmaceutical and life sciences including target identification, mechanism of action evaluation, biomarker discovery, and clinical trial support.

Kendra obtained a B.S. in Biochemistry from the University of Maryland, College Park graduating Summa Cum Laude and Phi Beta Kappa. She then obtained her Ph.D. in Biology, with a concentration in biochemistry, from The Johns Hopkins University. She was a Damon Runyan Cancer Research Foundation Postdoctoral Fellow at Duke University Medical Center.

Don Hertzog, Ph.D.

Don Hertzog, Ph.D., comes to Ribometrix from HemoShear Therapeutics where he was Head of Chemistry, leading all aspects of chemistry for HemoShear’s drug discovery programs in rare diseases. He previously served as Vice President of Early Lead Identification at Abide Therapeutics where he led a team of chemists devoted to identifying hit molecules and transforming them into leads worthy of further optimization to drug candidates.

Before joining Abide, Don was the site head for the Molecular Discovery Research Department of Medicinal Chemistry and Director of Medicinal Chemistry for Metabolic Diseases at GlaxoSmithKline, GSK, overseeing a team that progressed several molecules into preclinical development and clinical trials. This work was highlighted by Don’s leadership of the chemistry team that discovered GW856464, GSK’s clinical entry in the highly competitive field of MCH R1 antagonists for the treatment of obesity.

Don began his industrial career at Bayer Pharmaceuticals, where he was part of a team that advanced a glucagon antagonist into human trials for the treatment of type 2 diabetes. Dr. Hertzog earned his Ph.D. in organic chemistry from Emory University and a B.A. degree in chemistry from Hendrix College. He completed an NIH-sponsored postdoctoral fellowship at The Scripps Research Institute and has more than 40 total publications, patents, and invited presentations. Don was co-chair of the 2014 ACS National Medicinal Chemistry Symposium and has served as a member of the Long Range Planning Committee of the Medicinal Chemistry Division of the American Chemical Society, ACS.

Denise

"QUOTE"

Jonathan

"QUOTE"

Andy

"QUOTE"

Brittani

"QUOTE"

Caleb

"QUOTE"

Derek

"QUOTE"

Devon

"QUOTE"

Elizabeth

"QUOTE"

Karolina

"QUOTE"

Krista

"QUOTE"

Matt

"QUOTE"

Melissa

"QUOTE"

LaShanda

"QUOTE"

Melissa

"QUOTE"

Nick

"QUOTE"

Samir

"QUOTE"

Delita

"QUOTE"

Ariel

"QUOTE"

Chris

"QUOTE"

Paresh

"QUOTE"

Kevin Weeks, Ph.D.

David Corey, Ph.D.

Alain Laederach, Ph.D.

William S. Marshall, Ph.D.

Joshua Mendell, Ph.D.

Matthew S. Sigman, Ph.D.

Gene Yeo, Ph.D.

Kevin Weeks, Ph.D.

Kevin is a founder of Ribometrix and a Kenan Distinguished Professor of Chemistry at the University of North Carolina at Chapel Hill. The vision of his laboratory is to use chemical principles to explore the central role of RNA in biology with a focus on real-world problems and understanding human disease. RNA SHAPE technologies, invented in his laboratory, are used worldwide. The Weeks laboratory is applying SHAPE and other chemical technologies to challenging problems in biology, including the RNA-mediated reactions central to functions of mRNAs, lncRNAs, and viral RNAs.

Dr. Weeks obtained his BA with Honors and Department Honors in Chemistry from the College of Wooster and completed his Ph.D. at Yale, securing the Richard Wolfgang Prize for most Distinguished Dissertation in Chemistry. Dr. Weeks is a Fulbright and a Searle Scholar, an NIH EUREKA awardee, a Fellow of American Association for the Advancement of Science, a Life Member in Clare Hall at the University of Cambridge, and has taught many hundreds of undergraduates their first year chemistry.

David Corey, Ph.D.

David Corey received his Ph.D. in 1990 from Chemistry from the University of California, Berkeley under the guidance of Professor Peter Schultz and did his postdoctoral work at the University of California, San Francisco under the direction of Professor Charles Craik. In 1992 he joined the University of Texas Southwestern Medical Center and specializes in the molecular recognition of cellular nucleic acids.

Alain Laederach, Ph.D.

Alain Laederach, Ph.D. is an Associate Professor in the Biology department and the University of North Carolina, Chapel Hill. His main area of expertise is RNA bioinformatics, with a focus on developing algorithms and computational methods to study RNA structure and transcriptome scale.

Alain received his Ph.D. in Bioinformatics and Computational Biology from Iowa State University, and then went on to a post-doc at Stanford University (Genetics). His main area of research focuses on integrating large scale whole genome sequencing data with RNA structural probing experiments to identify structured, functional regions in the human transcriptome.

William S. Marshall, Ph.D.

William S. Marshall, Ph.D., is the President, Chief Executive Officer, Co-Founder and Director of miRagen, a company dedicated to improving patients’ lives through the discovery and development of innovative RNA-based therapeutics, with a specific focus on microRNAs. Prior to establishing miRagen, Dr. Marshall was Vice President of Technology and Business Development for Bioscience at Thermo Fisher Scientific. In this role, he was responsible for leading technology assessment and strategic planning for the Thermo Fisher Biosciences Division, a unit with revenues of approximately $1 billion that manufactures and supplies a wide range of products and services across the general-chemistry and life-sciences arenas.

Dr. Marshall was one of the scientific founders of Dharmacon, Inc., which was acquired by Fisher Scientific International, serving as the Executive Vice President for Research and Operations and General Manager. Prior to joining Dharmacon, Dr. Marshall served in many capacities at Amgen, Inc., most recently as Associate Director of Research, Site Head for Research and Head of the Nucleic Acid and Peptide Technology Department. In these positions, he participated in a wide variety of therapeutic development approaches throughout the drug discovery process leading to the development of clinical candidates.

Dr. Marshall earned his B.S. in Biochemistry from the University of Wisconsin-Madison and his Ph.D. in Chemistry in the laboratory of Professor Marvin Caruthers at the University of Colorado at Boulder. He is author and co-author of over 50 research papers and 80 patents. Dr. Marshall currently serves on the Board of FluoroFinder, LLC.

Joshua Mendell, Ph.D.

Dr. Joshua Mendell is a Howard Hughes Medical Institute Investigator, a Professor of Molecular Biology, and a member of the Harold C. Simmons Cancer Center and the Center for Regenerative Science and Medicine at the University of Texas Southwestern Medical Center, in Dallas, Texas.

Since 2004, Dr. Mendell has directed a research laboratory focused on investigating RNA biology in normal physiology and disease. In particular, the Mendell laboratory has devoted significant effort towards elucidating functions of noncoding RNAs, including microRNAs, miRNAs, and long noncoding RNAs, lncRNAs, and has made major contributions to our understanding of how these RNA transcripts contribute to diseases such as cancer.

For his work in this area, Dr. Mendell has been the recipient of several prestigious awards including the Allan C. Davis Medal for the Outstanding Young Scientist in the State of Maryland in 2007, the AACR Award for Outstanding Achievement in Cancer Research in 2010, and the O’Donnell Award from the Academy of Medicine, Engineering, and Science of Texas in 2016.

Matthew S. Sigman, Ph.D.

Matthew S. Sigman, Ph.D., is the Peter J. Christine S. Stang Presidential Endowed Chair of Chemistry at the University of Utah. He earned his B.S. at Sonoma State University, 1992, his Ph.D. at Washington State University, 1996, and was a NIH Postdoctoral Fellow, at Harvard University, 1997-1999.

Dr. Sigman’s research program is focused on the discovery of new practical catalytic reactions with broad substrate scope, excellent chemoselectivity, and high stereoselectivity to access novel medicinally relevant architectures. He believes the best strategy for developing new classes of catalysts and reactions applicable to organic synthesis is using mechanistic insights to guide the discovery process. This allows him to design new reaction motifs or catalysts in which unique bond constructions can be implemented furthering new approaches to molecule construction.

An underlying theme to these methodologies is to convert relatively simple substrates into much more complex compounds allowing for access to known and novel pharmacaphores in a modular manner. This provides the ability to readily synthesize analogs enabling the understanding of important structural features responsible for a phenotypic response in a given biological assay. Dr. Sigman is currently engaged in several collaborative projects to evaluate his group’s compound collections for various cancer types at the Huntsman Cancer Institute at the University of Utah and is engaged in follow-up investigations to identify improved compounds as well as understanding the mechanism of action.

Dr. Sigman’s awards include the Peter J. Christine S. Stang Presidential Endowed Chair of Chemistry, 2012-present, Fellow of the American Association for the Advancement of Science, 2011, U of U Distinguished Scholarly & Creative Research Award, 2011, Arthur C. Cope Scholar Award, 2010, Robert W. Parry Teaching Award, 2009, University of Utah Distinguished Honors Professor, 2008, NSF Faculty Early Career Development, CAREER Award, 2001-2006, Research Innovation Award, Research Corporation, 2000-2002, Camille Dreyfus Teacher-Scholar Award, 2004, Pfizer Award for Creativity in Organic Chemistry, 2004, NSF Faculty Early Career Development, CAREER Award, 2001-2006, and a Research Innovation Award, Research Corporation, 2000-2002

Gene Yeo, Ph.D.

Gene Yeo is a Professor of Cellular and Molecular Medicine at the University of California, San Diego, UCSD. Dr. Yeo has a BSc in Chemical Engineering and a BA in Economics from the University of Illinois, Urbana-Champaign, a Ph.D. in Computational Neuroscience from Massachusetts Institute of Technology and an MBA from the UCSD Rady School of Management. Dr. Yeo’s research interest is in understanding and manipulating RNA processing in development and disease using induced pluripotent stem cell and murine models. His lab demonstrated in vivo RNA targeting with CRISPR/Cas proteins with proof of concept in repeat expansion disorders. The Yeo research group members also developed enhanced CLIP for the purposes of large-scale mapping of protein-RNA interactions.

Gene’s lab is an active participant in RNA genomics technology and therapeutics development. Dr. Yeo is on the Editorial Boards of the journals Cell Reports and Cell Research. Dr. Yeo is a recipient of Alfred P Sloan Fellowship in recognition of his work in computational molecular biology (2011) and the inaugural Early Career Award from the International RNA Society (2017). Gene is a co-founder of several biotech companies including Locana, Eclipse Bioinnovations, Enzerna and Proteona. Gene serves or had served on the scientific advisory boards of the Allen Institute of Immunology, Locana, Eclipse Bioinnovations, Proteona, Aquinnah, LGC, Nugen and Ribometrix.

Mike Clayman, MD

Kevin Weeks, Ph.D.

Mike Ross, Ph.D.

John Gustofson, MBA

Mike Dial, Ph.D.

Hakan Goker, Ph.D.

William S. Marshall, Ph.D.

Mike Solomon, Ph.D.

Mike Clayman, MD

Mike Clayman, M.D., co-founded Flexion Therapeutics in 2007 and has since served as its president and CEO, guiding the discovery and development of ZILRETTA® for osteoarthritis-related knee pain. He also serves as chairman of the board of Anokion SA, a Swiss biotechnology company focused on treating autoimmune disease.

Before founding Flexion, Dr. Clayman had a distinguished career at Eli Lilly and Company, leading numerous divisions engaged in a broad range of activities, from discovery research to clinical investigation to global regulatory affairs. Among his roles, he served as general manager of Chorus, Lilly’s early-phase development accelerator, and as vice president of Lilly Research Laboratories. Prior to Lilly, Dr. Clayman was an assistant professor in the School of Medicine at the University of Pennsylvania, where his research centered on the immunopathogenesis of renal disease.

Dr. Clayman is the recipient of the Physician Scientist Award from the National Institutes of Health. He holds a B.A. from Yale University and an M.D. from the University of California, San Diego School of Medicine.

Kevin Weeks, Ph.D.

Kevin is a founder of Ribometrix and a Kenan Distinguished Professor of Chemistry at the University of North Carolina at Chapel Hill. The vision of his laboratory is to use chemical principles to explore the central role of RNA in biology with a focus on real-world problems and understanding human disease. RNA SHAPE technologies, invented in his laboratory, are used worldwide. The Weeks laboratory is applying SHAPE and other chemical technologies to challenging problems in biology, including the RNA-mediated reactions central to functions of mRNAs, lncRNAs, and viral RNAs.

Dr. Weeks obtained his BA with Honors and Department Honors in Chemistry from the College of Wooster and completed his Ph.D. at Yale, securing the Richard Wolfgang Prize for most Distinguished Dissertation in Chemistry. Dr. Weeks is a Fulbright and a Searle Scholar, an NIH EUREKA awardee, a Fellow of American Association for the Advancement of Science, a Life Member in Clare Hall at the University of Cambridge, and has taught many hundreds of undergraduates their first year chemistry.

Mike Ross, Ph.D.

Michael Ross, Ph.D. serves as a Managing Partner of SV Life Sciences, SVLS. He was the tenth employee at Genentech, where he worked for 13 years in various roles including team leader and Vice President of Development. Dr. Ross also started Genentech’s protein engineering and small molecule discovery effort as Vice President of Medicinal and Biomolecular Chemistry. He was the founding CEO of Arris Pharmaceutical, MetaXen, ExSAR and CyThera, now Novocell, and was also Managing Partner at Didyma, LLC, a biotechnology management consulting firm.

Dr. Ross currently serves or has served on the board of directors of several biotechnology companies, including Aderis Pharmaceuticals, Adimab, Alinea, Archemix, Arris Pharmaceuticals, Arsanis, Carta Proteomics, CyThera, Glycofi, Epimmune, Genencor, Ikano, Itero Biopharmaceuticals, Link Medicine, MetaXen, Mpex, NKT Therapeutics, Rempex, Rinat, Sutro Biopharmaceuticals and Xenova. He also serves on the faculty of Thayer School of Engineering at Dartmouth College.

Dr. Ross received his Bachelor of Arts, A.B., from Dartmouth College, his Doctor of Philosophy, Ph.D., degree in Chemistry from the California Institute of Technology, Caltech, and completed a Post-Doctorate program in Molecular Biology at Harvard University.

John Gustofson, MBA

John Gustofson is a Managing Director of AbbVie Ventures and invests across AbbVie’s therapy areas of Immunology, Oncology, and Neuroscience.

Prior to joining AbbVie, John worked at AstraZeneca as a Director of Strategic Partnering and Business Development focused on oncology licensing. John has 20+ years professional experience as a bench scientist and in various roles of market and business development. In addition John has worked in numerous biotechnology companies including Altus Pharmaceuticals, Therion Biologics, Boston Life Sciences and Ribozyme Pharmaceuticals. John also spent approximately 4 years in strategy consulting to the life sciences industry.

John holds a Master Degree in Molecular Biology from the Miami University and an MBA from the Boston University.

Mike Dial, Ph.D.

Experienced investor and scientist, Mike Dial has over a decade of experience working with early-stage life science and healthcare companies. Mike joined Hatteras in 2009 from Silicon Valley Bank, where he was a Vice President in the Corporate Finance Group focused on emerging tech and life science companies and venture capital funds. Prior to SVB, he held research scientist positions in the Department of Biochemistry at UNC-Chapel Hill, the Laboratory of Structural Biology at the National Institute of Environmental Health Sciences, and the UNC-Duke Michael Hooker Proteomics Center. He has performed research in the fields of cell cycle regulation, proteomics, and cancer therapy.

Mike is a Professor of the Practice at the Kenan-Flagler Business School at The University of North Carolina at Chapel Hill and is the Manager for the Carolina Research Ventures Fund, a $10M fund dedicated to UNC-Chapel Hill related start-ups. He holds a Ph.D. in Biochemistry and Biophysics from UNC-Chapel Hill.

Mike serves on the boards of Ribometrix, StrideBio, and Genturi and is a board observer at Spyryx. Previously, Mike was involved with G1 Therapeutics, Viamet, Lysosomal Therapeutics, Artizan Biosciences, and Curoverse among others, and has held various operational roles in Hatteras portfolio companies. Mike has also served on committees and panels for the North Carolina Biotech Center, Council for Entrepreneurial Development, SEBIO and PTP NEXT.

Hakan Goker, Ph.D.

Hakan Goker, Ph.D., is a senior investment director at M Ventures, corporate venture arm of the biopharmaceutical division of Merck KGaA, Darmstadt, Germany. Hakan has been investing for the past 12 years and joined M Ventures in 2013. Previously Hakan was a partner at Aescap Venture and prior to that was part of Atlas Venture life sciences team.

Since 2006, Hakan has been instrumental in the creation, financing, and corporate strategy of multiple biotechnology companies globally including Artios, Asceneuron, Storm, Bicycle, and F-star. Hakan received his PhD in cancer biology from the Institute of Cancer Research/ University of London and continued his scientific career with post-doctoral work at the Breakthrough Breast Cancer Centre/Royal Marsden Hospital. He gained his BSc Honours, from University College London. Hakan currently is a board member at Artios Pharma, Asceneuron, Forendo, Macrophage Pharma, Ribometrix Inc., Storm Therapeutics, Synaffix, Tocopherx, and is the chairperson of iOnctura.

William S. Marshall, Ph.D.

William S. Marshall, Ph.D., is the President, Chief Executive Officer, Co-Founder and Director of miRagen, a company dedicated to improving patients’ lives through the discovery and development of innovative RNA-based therapeutics, with a specific focus on microRNAs. Prior to establishing miRagen, Dr. Marshall was Vice President of Technology and Business Development for Bioscience at Thermo Fisher Scientific. In this role, he was responsible for leading technology assessment and strategic planning for the Thermo Fisher Biosciences Division, a unit with revenues of approximately $1 billion that manufactures and supplies a wide range of products and services across the general-chemistry and life-sciences arenas.

Dr. Marshall was one of the scientific founders of Dharmacon, Inc., which was acquired by Fisher Scientific International, serving as the Executive Vice President for Research and Operations and General Manager. Prior to joining Dharmacon, Dr. Marshall served in many capacities at Amgen, Inc., most recently as Associate Director of Research, Site Head for Research and Head of the Nucleic Acid and Peptide Technology Department. In these positions, he participated in a wide variety of therapeutic development approaches throughout the drug discovery process leading to the development of clinical candidates.

Dr. Marshall earned his B.S. in Biochemistry from the University of Wisconsin-Madison and his Ph.D. in Chemistry in the laboratory of Professor Marvin Caruthers at the University of Colorado at Boulder. He is author and co-author of over 50 research papers and 80 patents. Dr. Marshall currently serves on the Board of FluoroFinder, LLC.

Mike Solomon, Ph.D.

Mike has more than twenty years of experience in the biotechnology industry, with the last seventeen focused on creating and operating early stage therapeutic-focused companies.

Most recently, Mike was a Venture Partner at SV Health Investors which led the seed round for Ribometrix. Prior to that he was Chief Operating Officer at Decibel Therapeutics, a biotechnology company focused on broadly treating hearing disorders. Mike’s involvement at Decibel was part of his work as an Entrepreneur-in-Residence at Third Rock Ventures; he led a team that created Decibel’s business plan resulting in a $52 M Series A round.

Prior to Decibel, Mike was Chief Operating Officer at Ember Therapeutics, a Third Rock Ventures company focused on obesity and diabetes, and Chief Business Officer at Link Medicine, a neurodegeneration focused biotechnology company that was sold to Astra Zeneca. Mike was also a founder and VP of Discovery at Epizyme Therapeutics, a company focused on epigenetic modulators that is now a publicly traded company, and VP of Discovery at Hypnion, Inc a sleep disorder company that was sold to Lilly in 2007 for $325 million. Mike also spent two years as a biotechnology analyst at Bank of America Securities. He started his career at Millennium Pharmaceuticals, where he was project leader for multiple programs.

Mike received his BS in Chemistry from the University of Massachusetts at Amherst. He earned his Ph.D. in Organic Chemistry at the University of Wisconsin, and completed postdoctoral work in Synthetic Organic Chemistry at Scripps.